|: ABOUT US : PRODUCTS : NEWS : CAREERS : CONTACT US : HOME|
Sensera, Inc., of Chelmsford Massachusetts, is a development stage biological sensor company developing products for the Point of Care (POC) clinical diagnostics market. The Company has a unique sensor array technology that allows rapid, highly sensitive detection of proteins and DNA sequences. The technology is protected by four patents and features femtomolar sensitivity, allowing it to detect proteins like cardiac markers at a concentration at least an order of magnitude lower than current state-of-the-art assays. Sensera is incorporating this technology into a Point of Care (POC) Early & Rapid Analyzer (ER-A) to address unmet needs in the field of emergency medicine.
Sensera is positioning the (ER-A ) to initially address one rapidly growing market: Early Diagnosis of Myocardial Injury. ER-A’s high sensitivity for myocardial infarction indicators will enable the diagnosis of heart attacks (acute myocardial infarction or AMI) within two hours of the onset of chest pain, much earlier than possible with current tests. This eliminates the need for emergency personnel to wait for 6 hours in order to treat life-threatening AMI.The Company is in its product development stage and expects to begin clinical trials in 2006.
The Sensera management inlcudes:
Acting CEO - Samuel Straface, Ph.D.
Dr. Straface holds a Ph.D. in neurophysiology from the University of Western Australia.
President Hamed Borhanian
Mr. Borhanian holds an MS Degree in Mechanical Engineering from MIT, and a BE degree (honors) from McGill University.
CFO Mark Lebel
Lebel is co-founder and CFO of Sensera Inc. He has 20 years operations,
business development, strategic planning and entrepreneurship experience,
with P&L responsibility up to $250MM.
|© Sensera 2009|